An interventional study of Connected tools in Sleep Disorders, sponsored by University Hospital, Brest. Recruiting at 6 sites in France. Open to participants aged 6 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by University Hospital, Brest · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Sleep Wake Disorders with a site in France — 22 open to participants now, 27 under way, 4 of them phase 3. Sleep Wake Disorders · France.
Among the 65 studies in Sleep Wake Disorders with a site in France, this one is the 14th largest by planned enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2021, is one of 29 with no phase, reaches primary completion later than 15 of the 26 other live ones, and was the 22nd registered.
747 studies on the registry are indexed under Sleep Wake Disorders; 181 are open to participants now.
Browse Sleep Wake Disorders studies →22 of the 65 studies in Sleep Wake Disorders with a site in France are open now. Recruiting first, the newest first:
Replior AB · Sites in France
Ages 18–65
Direction Centrale du Service de Santé des Armées · Sites in France
Ages 18–65
Alkermes, Inc. · Sites in France, United States, Australia and 11 more countries
Ages 18–70
Alkermes, Inc. · Sites in France, United States, Australia and 12 more countries
Ages 18–70
University Hospital, Toulouse · Sites in France
Ages 18–65 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 114 Sleep Wake Disorders studies recruiting now, 40 (35%) set no upper age limit and 53 (46%) stop at 75 or younger; 22 take children under 18; 28 take healthy volunteers.
This study: 6 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6 · Phase 4 2
First in 2009; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 66 across 531 interventional studies indexed under Sleep Wake Disorders.
Median enrollment 87 across the 42 interventional studies, 100 across the 23 observational. Of the 31 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 65 have an industry lead sponsor. The 10 most frequent:
University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.
University Hospital, Brest has 1 study filed under Sleep Wake Disorders — fewer than ten, so there is no comparison to draw.
14 of the studies in Sleep Wake Disorders with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502443Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | 2027-05 |
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
| NCT07628959Centre Hospitalier Universitaire de Saint EtienneInnovative Sleep Quality Analysis Software Compared With Polysomnography | 2026-12 |
| NCT07909967Replior ABObservational Analytical Validation Study of the Replior ScratchSense | 2026-12-10 |
Add all 14 to your calendar (.ics) → With an account.
Among the 65 studies in Sleep Wake Disorders with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cerebral palsy (CP) is the most common cause of child disability. Nearly 40% of PC children suffer from sleep disorders, which are not routinely screened. The neuro-cognitive, physical and environmental morbidity of sleep disorders should require their diagnosis and management. Limited access to the reference exam (polysomnography or PSG) delays the diagnosis and only allows screening of these disorders for a limited number of PC children. The hypothesis of our study is that connected technologies could optimize screening for sleep disorders in PC children by selecting children requiring PSG exploration and specific management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1 night at home with connected tools only and 1 night at hospital with connected tools and PSG.
Procedure: Connected tools
At home, parents will record their child's sleep for 1night Then, on the date scheduled for the inclusion of the children and after the recording of the 1 night at home, the child will spend a night in a hospital environment to carry out the recording by polysomnography and tools connected simultaneously.
Sensitivity of the diagnosis of sleep disorder
Sensitivity of sleep disorder diagnosis (positive / negative) obtained using connected tools in reference to that obtained by PSG
Time frame: 15 days
Specificity of the diagnosis of sleep disorder
Specificity of sleep disorder diagnosis (positive / negative) obtained using connected tools in reference to that obtained by PSG
Time frame: 15 days
Diagnosis
Sensitivity and specificity of sleep disorder diagnosis using tools connected during 1 night at home (in comparaison with sleep disorder diagnosis using PSG)
Time frame: 15 days
Acceptability assessed by acceptability score for parents, and if possible children
Acceptability assessed by the acceptability score for parents, and if possible children, obtained by the SUS "System Usability Scale" scale. This questionnaire consists of ten questions to collect the subjective point of view of the user on the systems used
Time frame: 15 days
Sleep Quality Questionnaire
Sleep quality questionnaire used as a screening tool for sleep disorders: use of the Sleep Disturbance Scale for Children. Sleep Disturbance Scale for Children (SDSC) is a screening tool for sleep disorders in children and adolescents with good psychometric properties. It is one of the most used sleep questionnaires in the clinic but also in clinical research. Since its creation, the SDSC has been translated into several languages and recently validated in French. The ranking is obtained from a 26-item questionnaire completed by the parents. This scale distinguishes 6 major groups of sleep disorders: disorders of the installation or maintenance of sleep, breathing disorders, waking disorders, sleep-wake transition disorders, excessive daytime sleepiness and hypersudation of sleep.
Time frame: 15 days
Data quality outcome measures
Data quality will be assessed by establishing for each sensor the ratio (expressed in percent value) between the duration of the data effectively recorded to the total duration the patient weared the sensors. Pauses in recording during recording sessions will be identified in absolute value and duration for each sensor. Specific issues in recording will be reported, especially regarding the contents of RAW files.
Time frame: 25 months
A cost analysis of the sensor screening strategy will be compared to the PSG and the quality of life
A cost analysis of the sensor screening strategy will be compared to the PSG and the quality of life, measured as quality-adjusted life year QALY, will be simulated for one-year health conditions.
Time frame: 25 months
Started Jan 2021 (actual). Primary completion is estimated for Feb 2027, 73 months after the start.
Of 214 non-industry interventional studies with no phase under Sleep Wake Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 40. This study's planned 73 months is above that.
Counting every sponsor, half of 249 studies reached it within 19 months; a quarter within 6 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.